COVID-19 is a pneumonia-like disease, which is caused by a novel coronavirus \[[@bib1]\]. Coronavirus belongs to Orthocoronavirinae subfamily of the Coronaviridae family within the order Nidovirales. COVID-19 is the defining global health crisis that has spread over 205 countries including USA, Italy, Russia, Spain, Japan, Korea, Iran, and Germany \[[@bib2],[@bib3]\]. By the end of December 2019, a serious pneumonia like cluster of cases with unknown source expanded globally from Wuhan, China \[[@bib4]\]. Various reports suggest that the novel coronavirus is 96.2% identical to a bat CoV RaTG13 \[[@bib5],[@bib6]\]. Evolutionary analysis of virus genome has suspected bat as a natural host of the virus origin that could have been transmitted from an unknown intermediate host to the humans \[[@bib7]\]. The infection poses a significant risk to patients with COVID-19 due to the high frequency of pneumonia, fever, and dry cough. Additionally, patients suffer from the potential damage of vital organs, especially the lungs, heart, liver, and kidneys \[[@bib8], [@bib9], [@bib10]\]. As per the latest reports from China, the mortality rate of COVID-19 disease is approximately 3--4% \[[@bib11]\]. The latest data obtained on 30 June 2020 describes that COVID-19 has infected more than Ten million people worldwide. Amongst these cases, 5.6 million have been successfully treated and 5,08,422 has died. The number of infected people is increasing every day by one thousand worldwide.

Recently, severity model based analysis has showed that the fatality ratio for China is 0·66%, on the Diamond Princess ship is 2.3%, and the large meta-analysis of 36 European countries showed the case-fatality rate of COVID-19 range of 4%--4.5% with an increasing profile with age \[[@bib12], [@bib13], [@bib14]\]. Furthermore, in current scenario, India is ranked as the fourth highest country with positive cases and a case-fatality rate of 1.9--3.6% \[[@bib15]\]. In the current situation, a second wave of coronavirus has hit the major cities of European countries including Sao Paulo and Rio de Janeiro, which is the centre for pandemic. Till date, more than 1.3 million positive cases have been identified in Brazil \[[@bib16]\]. In Russia, more than 687,862 cases and 10,296 deaths due to COVID-19 infection has been reported \[[@bib17]\].

In order to treat COVID-19, the only available treatment currently available is the retroviral therapy. Further, it was proven that convalescent plasma transfusion (CPT) is useful against COVID-19 \[[@bib18],[@bib19]\]. At this crucial moment, in-depth research is essential to treat and prevent the disease. Several researchers have promptly carried out clinical research aimed towards the diagnosis, treatment, and prevention of COVID-19 \[[@bib20]\]. However, globally there is limited information available to analyze and summarize the registered clinical trials. The purpose of this review is to summaries existing COVID-19 clinical trial data that would aid in selecting the most appropriate COVID-19 treatment.

Search Strategy And Selection Criteria {#sec1}
======================================

Using various keywords related to COVID-19 including comorbidities, clinical characteristics, epidemiological, immunotherapy, vaccine, and SARS CoV-2 clinical trial data were obtained from different electronic databases. Some of these databases were European union clinical trials database, Clinical Trial Registry, Clinicatrial.gov, International Clinical Trials Registry Platform (WHO ICTRP), Chinese Biomedical Literature Database, and the Wanfang Database. Pubmed, the National Library of Medicine (NLM), and EMBASE database were also used to identify ongoing trials.

Literature Inclusion And Exclusion Criteria {#sec2}
===========================================

All investigators have selected only the most appropriate and suitable studies. Inclusion criteria encompasses the following: (1) studies of COVID-19 patients' clinical trials, (2) detailed protocol of clinical trials, (3) data mining, (4) the original design type (Interventional or observational), (5) reports that involved the treatment of COVID-19. The exclusion criteria includes the following: (1) studies having duplicate data and (2) vague theoretical research and unregistered clinical trials.

Quality Assessment {#sec3}
==================

Quality of clinical data and extracted data from the literature were assessed by rigorous information cross-check. Discrepancy between the investigators was resolved and the final decisions were decided without any conflicts. Relevant data was summarized in a narrative manner and the treatment strategy was grouped. Each table was categorized according to the drug usage. Results were classified based on the type of study, country, dose, duration of administration, an indication of medication, and the number of patients included in the study.

Results {#sec4}
=======

Trial search outcomes {#sec4.1}
---------------------

34 clinical trials from the European Union clinical trial database and 26 clinical trials from the National Institute of Health (NIH) clinical trial database were retrieved and presented in the flow chart \[[Fig. 1](#fig1){ref-type="fig"} \]. A total of 60 clinical trials of COVID-19 were classified as either active, completed, or recruiting. 8 patients used hydroxyquinone alone or in combination with other drugs, 6 used remdesivir, 5 used Tocilizumab, Lopinavir/ritonavir either single or combined, 4 used Interferon alpha and beta, and 4 patients used Plaquenil. All other remaining cases used different types of molecules or interventions \[[Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"} \]. Above all, most of the trials have cleared the ethical approval. Some of the case studies are still in the recruitment phase, whereas 20 trials have begun recruiting patients. Amongst them, only 4 trials are in active phase and in the next few days, patient recruitment will begin. 2 clinical trials are still incomplete.Fig. 1Flowchart of study selection for the present study.Fig. 1Table 1List of various combination strategies used in current WHO clinical trials in the treatment of COVID-19.Table 1NOsNCT NumberTitleStatusInterventionsSponsorAgePhasesEnrollmentStudy TypeStart DateCompletion1.[NCT04333420](NCT04333420){#intref0010}Open label, randomized phase ii/iii study of ifx-1 in patients with severe covid-19 pneumoniaRecruitingBest supportive\
Care (BSC) + IFX-1\|InflaRx GmbH18 Years and olderPhase 2 Phase 3130Interventional31-Mar-2031-Dec-202.[NCT04306497](NCT04306497){#intref0015}Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.RecruitingTCM prescriptionsJiangsu Famous Medical Technology Co., Ltd.18 Years--75 YearsNA340Observational02-Mar-20May-203.[NCT04292899](NCT04292899){#intref0020}Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734„¢) in Participants With Severe Coronavirus Disease (COVID-19)RecruitingRemdesivirGilead Sciences18 Years and olderPhase 3400Interventional06-Mar-20May-204.[NCT04292730](NCT04292730){#intref0025}Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care TreatmentRecruitingRemdesivirGilead Sciences18 Years and olderPhase 3600Interventional15-Mar-20May-205.[NCT04324489](NCT04324489){#intref0030}DAS181 for Severe COVID-19: Compassionate UseRecruitingDAS181Renmin Hospital of Wuhan University\|Ansun Biopharma, Inc.18 Years--70 YearsNA4Interventional06-Mar-2030-Apr-206.[NCT04330690](NCT04330690){#intref0035}Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialActive, not recruitingLopinavir/ritonavirSunnybrook Health Sciences Centre\|AbbVie6 Months and olderPhase 2440Interventional18-Mar-20NA7.[NCT04324021](NCT04324021){#intref0040}Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.RecruitingEmapalumab, AnakinraSwedish Orphan Biovitrum30 Years--79 YearsPhase 2 Phase 354InterventionalApr-20Sep-208.[NCT04327388](NCT04327388){#intref0045}Sarilumab COVID-19RecruitingSarilumabSanofi\|Regeneron Pharmaceuticals18 Years and olderPhase 2\|Phase 3300Interventional28-Mar-20Jun-219.[NCT04334954](NCT04334954){#intref0050}SARS-COV2 Pandemic Serosurvey and Blood SamplingRecruitingNANational Institute of Allergy and Infectious Diseases (NIAID)18 Years and olderNA1000Observational09-Apr-2031-Mar-2210.[NCT04325646](NCT04325646){#intref0055}Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological SamplesRecruitingHuman Biological samplesInstitut Pasteur5 Years and olderNA1000Observational13-Mar-2028-Feb-2311.[NCT04328129](NCT04328129){#intref0060}Household Transmission Investigation Study for COVID-19 in French GuianaRecruitingHuman biological samplesInstitut Pasteur5 Years and olderNA450Interventional23-Mar-2023-Mar-2212.[NCT04280705](NCT04280705){#intref0065}Adaptive COVID-19 Treatment Trial (ACTT)RecruitingRemdesivirNational Institute of Allergy and Infectious Diseases (NIAID)18 Years--99 YearsPhase 3440Interventional21-Feb-2001-Apr-2313.[NCT04313127](NCT04313127){#intref0070}A Phase I Clinical Trial in 18--60 AdultsActive, not recruitingAdenovirus Type 5\
VectorCanSino Biologics Inc.\|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China\|Jiangsu Province Centers for Disease Control and Prevention\|Hubei Provincial Center for Disease Control and Prevention\|Tongji Hospital18 Years--60 YearsPhase 1108Interventional16-Mar-2020-Dec-2214.[NCT04321811](NCT04321811){#intref0075}Behavior, Environment And Treatments for Covid-19RecruitingHuman Biological samplesxCures\|Genetic Alliance\|LunaDNA\|Cancer Commons\|REDCap Cloud18 Years and olderNA100000Observational21-Mar-2020-Mar-2215.[NCT04333654](NCT04333654){#intref0080}Hydroxychloroquine in Outpatient, Adults With COVID-19RecruitingHydroxychloroquineSanofi18 Years and olderPhase 1210Interventional31-Mar-20May-2016.[NCT03808922](NCT03808922){#intref0085}Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyRecruitingDAS181Ansun Biopharma, Inc.5 Years and olderPhase 3250Interventional23-May-1928-Dec-2117.[NCT04291729](NCT04291729){#intref0090}Evaluation of GanovôDanoprevir Combined With Ritonavir in the Treatment of Novel Coronavirus InfectionCompletedGanovo+ritonavir ± Interferon nebulizationThe Ninth Hospital of Nanchang\|Ascletis Pharmaceuticals Co., Ltd.18 Years--75 YearsPhase 411Interventional17-Feb-2019-Mar-2018.[NCT04334928](NCT04334928){#intref0095}Clinical Trial for the Prevention of SARS-CoV-2Infection in Healthcare Personnel (EPICOS)Active, not recruitingEmtricitabine/tenofovir disoproxil\|HydroxychloroquinePlan Nacional sobre el Sida (PNS)\|Effice Servicios Para la Investigation S.L.18 Years--65 YearsPhase 34000Interventional01-Apr-2031-Jul-2019.[NCT04321369](NCT04321369){#intref0100}Impact of Swab Site and Sample Collector on Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic IndividualsCompletedDiagnostic testsDr. Deneen Vojta\|Quest Diagnostics\|Bill and Melinda Gates Foundation\|UnitedHealth Group5 Years and olderNA533Observational09-Mar-2023-Mar-2020.[NCT04327804](NCT04327804){#intref0105}A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for ResearchRecruitingDiagnostic TestDr. Deneen Vojta\|PATH\|Mayo Clinic\|Bill and Melinda Gates Foundation5 Years and olderNA120Observational25-Mar-2010-Apr-2021.[NCT04283461](NCT04283461){#intref0110}Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 InfectionRecruitingmRNA-1273National Institute of Allergy and Infectious Diseases (NIAID)18 Years--55 YearsPhase 145Interventional03-Mar-2001-Jun-2122.[NCT03331445](NCT03331445){#intref0115}Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) InfectionsActive, not recruitingNitric Oxide 0.5%/Nitrogen 99.5% Gas for InhalationUniversity of British Columbia\|Mallinckrodt14 Years and olderPhase 220Interventional24-Oct-1731-Mar-2123.[NCT04331171](NCT04331171){#intref0120}Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients\' TriageRecruitingDeviceWeprom\|Institut Pasteur\|Assistance Publique - HÃ\'pitaux de Paris\|DOCAPOST\|Direction GÃ©nÃ©rale de l\'Offre de Soins18 Years and olderNA3000000Observational17-Mar-2031-Jul-2024.[NCT04321278](NCT04321278){#intref0125}Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)RecruitingHydroxychloroquine + azithromycinHospital Israelita Albert Einstein\|EMS\|Hospital do Coracao\|Hospital Sirio-Libanes\|Brazilian Research In Intensive Care Network\|CristÃ¡lia Produtos QuÃmicos FarmacÃ^a^uticos Ltda.18 Years and olderPhase 3440Interventional28-Mar-2030-Aug-2025.[NCT04326309](NCT04326309){#intref0130}Audio Data Collection for Identification and Classification of CoughingRecruitingNAHealthMode Inc.18 Years and olderNA1000Observational25-Mar-2025-Sep-22Table 2Characteristics of ongoing European Union Clinical Trials studying the efficacy and safety of Chloroquine, Tocilizumab, Lopinavir/ritonaviror other related formulation for patients with novel coronavirus pneumonia (COVID-19).Table 2S.NoSponsor NameProtocol NoStudy TitleStart DateOngoing/CompletedPopulation AgeNo. of SubjectMedical ConditionActive SubstancesLevelRoutCountry/National Competent Authority1Akershus University HospitalAhus--NO--COVID-19Norwegian coronavirus disease 2019 (no covid-19) study: an open labeled randomized controlled pragmatic trial to evaluate the antiviral effect of chloroquine in adult patients with sars-cov-2 infection2020-03-23OngoingAdults, Elderly (18--64)200SARS-COV-2 infectionhydroxychloroquine sulfate\
200 mgLLTOralNorway2University of Oxford/Clinical Trials and Research GovernancePRINCIPLEPlatform Randomised trial of interventions against COVID-19 In older people2020-03-26OngoingAdults, Elderly (18--64)3000Suspected COVID-19Hydroxychloroquine Sulfate\
200 mgPTOralUK - MHRA3Department of Infectious Diseases, Aarhus University HospitalCamoCO-19-001The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase iia trial2020-03-30OngoingAdults, Elderly (18--64)1802019-nCoV acute respiratory diseaseCamostat mesilate\
100 mgLLTOralDenmark - DHMA4University Hospital GhentSARPACA prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients wit ...2020-03-24OngoingAdults, Elderly (18--64)80Acute hypoxic respiratory failure of COVID-19 patientsSargramostim\
250ugLLTIntravenousBelgium - FPS Health-DGM5Hellenic Society of RhythmologyGRECCO-19The Greek study in the Effects of Colchicine in Covid-19 complications prevention2020-04-01OngoingAdults, Elderly (18--64)180myocardial necrosis and pneumonia development in the context of COVID-19ColchicinePTIntravenousGreece - EOF6Azienda Unità Sanitaria Locale-IRCCS di Reggio EmiliaRCT-TCZ-COVID-19Uno studio randomizzato multicentrico in aperto per valutare l\'efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-192020-03-27OngoingAdults, Elderly (18--64)398COVID-19 infectionTocilizumab\
20 mg/mlPTIntravenousItaly - Italian Medicines Agency7CHU Angers49RC20_0071HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d\'aggravation secondaire: étude prospective multicentrique randomisée en double aveugle2020-03-31OngoingAdults, Elderly (18--64)1300Covid-19Hydroxychloroquine\
200 mgLLTOralFrance - ANSM8F. Hoffmann-La Roche LtdWA42380A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe covid-19 pneumonia.31-03-20OngoingAdults, Elderly (18--64)50COVID-19 pneumoniaTocilizumab\
20 mg/mlPTIntravenousFrance - ANSM9Regents of the University of Minnesota10A Multicenter, Adaptive, Randomised, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U ...25-03-20OngoingAdults, Elderly (18--64)100,\
50,\
40Influenza COVID-19Remdesivir\
100/200 mgHLTIntravenousDenmark - DHMA & UK - MHRA10UZLeuvenS63874Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-cov-2.26-03-20OngoingAdults, Elderly (18--64)200COVID-19itraconazoleLLTIntravenousBelgium - FPS Health-DGM11Sanofi-aventis recherche & développementEFC16858An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-192020-04-02OngoingAdults, Elderly (18--64)40, 50Coronavirus infectionPlaquenil 200 mgPTOralUK -- MHRA, France - ANSM12InflaRx GmbHIFX-1-P.2.9A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - "PANAMO"2020-03-29OngoingAdults, Elderly (18--64)47Severe pneumonia in context of COVID-19IFX-1PTIntravenousNetherlands - Competent Authority13GUSTAVE ROUSSY2020/3078COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients2020-04-03OngoingAdults, Elderly (18--64)1000Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies.hydroxychloroquineLTTOralFrance - ANSM14Amsterdam UMCCOVID-19COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19 -- a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease2020-03-31OngoingAdults, Elderly (18--64)304Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease.Imatinib mesilateNAOralNetherlands - Competent Authority15ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"TOCIVID-19Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia2020-03-18OngoingAdults, Elderly (18--64)330COVID-19Tocilizumab\
20 mg/mlPTIntravenousItaly - Italian Medicines Agency16Synairgen Research LimitedSG016A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (ifnβ-1a for nebulisation) for the treatment of patients with confirmed SARS-cov-2 infectio ...2020-03-17OngoingAdults, Elderly (18--64)200COVID-19Interferon beat-1a (IFN-β1a)LLTIntravenousUK - MHRA17Assistance Publique - Hôpitaux de ParisAPHP200375Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients2020-03-25OngoingAdults, Elderly (18--64)1000COVID-19KevzaraLLT,IntravenousFrance - ANSM18DRCI APHPAPHP200394Protective role of inhaled steroids for COVID-19 infection2020-04-05OngoingAdults, Elderly (18--64)Not announcedCOVID-19BudesonideNAInhalationFrance - ANSM19Gilead Sciences, Inc.GS-US-540-5774A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment2020-03-18OngoingAdults, Elderly (18--64)35, 35, 35,40,50,100COVID-19Remdesivir\
100 mgLLTIntravenousGermany - BfArM, Spain - AEMPS, France - ANSM, France - ANSM, Netherlands - Authority, UK - MHRA, Sweden - MPA20Gilead Sciences, Inc.GS-US-540-5773A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-192020-03-18OngoingAdolescents, Under 18, Adults, Elderly200, 20, 20, 45, 40, 100, 100Coronavirus disease 2019 (COVID-19)Remdesivir\
100 mgLLTIntravenousGermany - BfArM, Spain - AEMPS, France - ANSM, France - ANSM, Netherlands - Competent Authority, UK - MHRA, Sweden - MPA21APEIRON Respiratory Therapies GmbHAPN01-01-COVID19Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-192020-04-03OngoingAdults, Elderly (18--64)50Severe COVID-19 POSITIVE hospitalized male or female, between 35 and ≤80 years of ageRecombinant human angiotensin-converting enzyme 2NAIntravenousDenmark - DHMA22Oslo University HospitalWHO-NOR-COVID-19The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-cov-2 infected patients (COVID-19)2020-03-26OngoingAdults, Elderly (18--64)443SARS-COV-2 infectionPlaquenilLLTOralNorway - NOMA23CHU de Saint Etienne20CH065Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.2020-03-30OngoingAdults, Elderly (18--64)50covid-19Hydroxychloroquine sulfate\
400--800 mgLLT, PTOralFrance - ANSM24University of OxfordNDPHRECOVERYRandomised Evaluation of COVID-19 Therapy (RECOVERY)2020-03-17OngoingAdults, Elderly (18--64)Not announcedCOVID-19 (infection with SARS-CoV-2 virus)Lopinavir/ritonavir\
200 mgPT, PTOralUK - MHRA25Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection202002102Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine2020-03-05OngoingAdolescents, (12--17), Adults, Elderly\
(18--64)25Patients with documented respiratory infection with coronavirus SARS COV 2Plaquenil 200 mgLLT,OralFrance - ANSM26University Hospital GhentCOV-AIDA prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard \...2020-04-03OngoingAdults, Elderly (18--64)342COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome.RoActemraIntravenousBelgium - FPS Health-DGM27INSERMC20-15Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults2020-03-09OngoingAdults, Elderly (18--64)1000COVID-19 -Plaquenil 200 mgLTTOralFrance - ANSM28Universitätsklinikum TübingenCOV-HCQRandomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 -- COVID-192020-03-25OngoingElderly (\>65)220Acute coronavirus disease 2019Chloroquine phosphate\
200 mgPTOralGermany - BfArM29Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.UNIKINON-01/HOPECHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-cov-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL2020-04-02OngoingAdults, Elderly (18--64)60pneumonia from SARS-CoV-2 in patients staying home and improving symptoms of SARS-CoV-2 pneumonia in patients treated in hospitalTocilizumabLLTIntravenousGreece - EOF30Sanofi-aventis Recherche et DéveloppementEFC16844An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-192020-03-26OngoingAdults, Elderly (18--64)25, 40, 25Corona virus infectionHydrocortisonePTIntravenousGermany - BfArM, France - ANSM, Italy - Italian Medicines Agency31University Medical Center73249Reducing health care workers absenteeism in SARS-cov-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19).2020-03-17OngoingAdults, Elderly (18--64)1000SARS-CoV-2 infectionBCG-CORONAHLTIntravenousNetherlands - Competent Authority32Hellenic institute for the study of sepsisESCAPEEfficiency in management of organ dysfunction associated with infection by the novel sars-cov-2 virus (covid-19) through a personalized immunotherapy approach: the escape clinical trial2020-04-01OngoingAdults, Elderly (18--64)20Organ dysfunction by the novel SARS-Cov-2 virusTocilizumab\
400 mgLLTIntravenousGreece - EOF33The Parker Institute, Bispebjerg and Frederiksberg Hospital,APPI2-CV-2020-01Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial2020-04-3OngoingAdults, Elderly (18--64)200SARS-CoV-2 infectionTocilizumab\
400 mgLLTIntravenousDenmark - DHMA34University Medical Center UtrechtREMAP-CAPRandomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)2015-09-16OngoingAdults, Elderly (18--64)600,600, 40, 800, 200, 270, 600,30, 60, 152Severe Community Acquired PneumoniaLevofloxacinLLTIntravenousNetherlands, Ireland, Portugal, UK- MHRA, Hungary, Belgium, Germany, Croatia, Spain, FRance[^1]

The first randomized controlled clinical pathways were sponsored by Dongzhimen Hospital of the Beijing University of Traditional Chinese Medicine (medical aspects of traditional knowledge that developed over generations). Those drugs were registered as "Chinese Severe Pneumonia Medicine with Severe Coronavirus Pneumonia" on 3 January 2020. In this review, we have included 60 trials in terms of clinical trial phases. Amongst them, 43 trials are in the preliminary experimental phase, 7 are in the middle phase, 8 are in phase 3 and extended for validation. 1 trial is completed with Ganovo+ritonavir ± Interferon nebulization drugs and ready for sale as the same diagnostic kit (Quest Diagnostics, Bill and Melinda).

Intervention and evaluation {#sec4.2}
---------------------------

The leading intervention strategy of registered clinical trials consists of traditional Chinese medicine, western medicine, and conventional integrated treatment. Especially, the outcome of therapy includes treatment time, patient immunity, frequency of use of ventilation, mortality, number of complications, and virological detection indicators. Current duration of the medication is more than 10 days. Medicinal approaches include oral, injection, and inhalation. The control subject was treated regularly with a placebo. At present, 24 western medicinal treatments are registered in clinical trials. On the other hand, single or combination of biological agents such as hydroxychloroquine, camostat mesilate, sargramostim, colchicine, tocilizumab, remdesivir, Itraconazole, IFX-1, Imatinib mesilate, Interferon beta-1a (IFN-β1a), Sarilumab, Budesonide, and Nitric Oxide 0.5%/Nitrogen 99.5% Gas for Inhalation, Recombinant human angiotensin-converting enzyme 2, Plaquenil, lopinavir/ritonavir, RoActemra, Chloroquine phosphate, Hydrocortisone, Levofloxacin, Emapalumab, Anakinra, Sarilumab, Danoprevir+ritonavir ± Interferon, Emtricitabine/tenofovir are listed as intervention methods.

Two clinical trials include biological agents product mRNA, blood stem cells, cord blood mononuclear cells, mesenchymal stem cell (MSC), recombinant cytokine gene-derived vector, and immunoglobulin (IgM, IgG).

Discussion {#sec5}
==========

Since the impact of COVID-19 is extremely severe, the development of an effective treatment strategy against the infection is very critical and concerning throughout the world. Although the molecular diagnosis, treatment, and international public health has improved after experiencing the 2003 SARS (CoV-I) epidemic, due to the new mutant form of the COVID virus, it is difficult to diagnose and treat the infection. Moreover, there is no proven or recognized licensed therapy against COVID-19. This sudden event has caused a high mortality rate in China and other countries around the world, mainly the European regions. The current situation leads us to carry out a systematic review to summarize the on-going clinical trials and possible therapeutic options against COVID-19 \[[@bib1],[@bib11],[@bib21]\]. Intensive clinical trials are being conducted by many researchers to eradicate this disease.

Most of the reports demonstrate the intervention of western medicine and a combination of traditional medicine to treat COVID-19 infection. Most of the studies are still in the preliminary experimental phase of the clinical trail. There are 43 extended (Phase 1) trial studies that show the utilization of drugs (Hydroxychloroquine, Camostat mesilate, Sargramostim, Colchicine, Tocilizumab, Remdesivir, Itraconazole, IFX-1, Imatinib mesilate, Interferon beta-1a (IFN-β1a), Kevzara, Budesonide, Lopinavir/ritonavir, RoActemra, Chloroquine phosphate, Hydrocortisone, Levofloxacin, Emapalumab, Anakinra, Sarilumab). According to the population size used in the clinical trial, 18 interventional clinical trials were carried out, which included 4 to 4000 candidates/trials and 8 observational studies, that included around 1000 to 3000000 candidates. Most of the trials are on-going; thus, the confirmation level and the clinical significance is limited \[[Table 1](#tbl1){ref-type="table"}\].

The alternative strategy to fight against COVID-19 is mainly based on boosting immune responses and to prevent the disease complications. This strategy improves patient immunity by predominating self-immune damage to the cytokine storm (modulating the post-infection immune response) and symptomatic treatment \[[@bib22]\]. Although some Chinese herbs have shown both antiviral and high immune effects, current situations prove that the antiviral effect of western drugs is superior and tolerable in comparison to the traditional ayurvedic, Unani, or homeopathic medicines \[[@bib23],[@bib24]\]. The combination of Qingfeipaidutang and hydroxychloroquine phosphate might be a potential therapeutic strategy for the treatment and management of COVID-19 \[[@bib25],[@bib26]\]. Recently, an open-label, randomized clinical trial of standard medical treatment or colchicine (1.5-mg loading dose by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) in 105 patients showed that event-free survival time was 20.7 days in the colchicine group and 18.6 days in the control group and a significantly improved time to clinical deterioration \[[@bib27]\]. Another multicenter, open-label randomized controlled trial in 160 patients with Shenhuang granule (50 g of *Panax ginseng* C. A. Mey, 40 g of *Rheum palmatum* L. stem, 30 g of *Sargentodoxa cuneata* stem, 30 g of *Taraxacum mongolicum*, 50 g of Aconiti Lateralis Radix Praeparata, and 6 g of Whitmania pigra Whitman) twice a day for 14 days is underway and the trail results are awaiting \[[@bib28]\].

Still, there is a lack of high-grade substantiation evidence that demands further clinical clarification and verification. Several clinical researchers have used biological products for the treatment of COVID-19. In order to treat COVID-19 infection, Steroid-based therapy has been implemented and the result availability is limited for trials \[[@bib13],[@bib29]\]. The most commonly used drug is chloroquine (anti-malaria) and ribavirin with a broad-spectrum antiviral combination of Remdesivir and IFN-α2b. An interventional study based in Spain was registered at ClinicalTrials.gov on 1 April 2020 (ID: NCT04334928). Currently, this is the only clinical trial underway with Emtricitabine/tenofovir disoproxil/hydroxychloroquine against COVID-19 infection. Due to minimal interaction, the combination of baricitinib and lopinavir/ritonavir/remdeviate antivirals was used to treat the infection COVID-19 during the pandemic. The combination of baricitinib and above-mentioned drugs may reduce viral replication, infectivity, and aberrant host inflammatory response \[[@bib30]\].

Future perspective {#sec5.1}
------------------

In most trials, inclusion and exclusion criteria has eliminated children under 18 years, pregnant women, and comorbidities like liver, heart, and kidney disease. This may result in a lack of substantial clinical evidence. The quality of clinical research needs to improve drastically. Registered clinical trials must follow Observatory/Interventional Clinical Trial Guidelines. Clinical trials must not be registered without accurate drug testing. Safety guidelines for *in vitro* experiments during clinical trials are a major concern. Thus, The National Science Research Administration (NASR) should consider improving the health risks assessment, good research practice, and coordination of fewer promising drugs i.e.; Remdesivir. Moreover, a major limitation of the registered clinical studies is that most of them follow a traditional conservative approach without considering the timeline.

Conclusion {#sec6}
==========

Due to the lack of intensive and high-quality clinical evidence, there is no final consent to the ideal therapy for COVID-19. It is difficult to obtain reliable data even with a small sample size and prolonged study periods. There is a undoubted need for protocol development that can be used for large randomized clinical trials. In order to establish such clinical trials, prospective therapies must be designed. The NASR must improve the good clinical practice in research and coordination along as well as aid in improving the efficacy and quality of the study that could deal with current health emergencies. Besides, during clinical trials, the implementation of a variety of study designs with a large number of cases and different statistical analyses is crucial. Further; we must recognize the ancient history report of previous infectious diseases in order to implement novel conceptual health-related policies.
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